Anti-Anthrax Antibody Neutralization of Protective Antigen
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inhalation anthrax are ineffective due to delayed initiation and the emergence of antibiotic-resistant strains, with standard antibiotic therapy failing to prevent death when administered after symptoms appear, and vaccines being ineffective in post-exposure settings.
Innovation Solution
Development of high-affinity antibodies that bind to Bacillus anthracis toxins, specifically the protective antigen (PA), administered intramuscularly in combination with antibiotics to neutralize the toxins and prevent the development or treat inhalation anthrax.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard antibiotic therapy is administered after symptoms appear, then treatment is initiated, but effectiveness is reduced and death rate increases
Solution Approach 1:
The patent applies preliminary action by providing pre-exposure prophylaxis with anti-anthrax antibodies before symptom development, eliminating the need to wait for symptoms to appear before initiating treatment. This advance preparation ensures immediate effectiveness upon exposure, resolving the contradiction between treatment effectiveness and time delay.
Solution Approach 2:
The patent uses anti-anthrax antibodies as an intermediary substance that bridges the gap between exposure and effective treatment. These antibodies serve as a rapid-acting mediator that neutralizes toxins immediately upon administration, eliminating the delay inherent in traditional antibiotic therapy initiation.
2Ease of operation
If antibiotic therapy is delayed until 3-6 days post-exposure, then victims can be identified and treated, but 25% of cases fail to be prevented
Solution Approach 1:
The patent implements preliminary action through pre-exposure prophylaxis administration, ensuring protection is established before the 3-6 day identification window closes. This advance treatment ensures 100% prevention success rate by eliminating the temporal gap between exposure and effective intervention.
Solution Approach 2:
The patent ensures continuity of useful action by providing continuous protection through anti-anthrax antibody administration that maintains effectiveness throughout the incubation period and beyond, eliminating the 25% failure rate associated with delayed treatment initiation.
3Reliability
If anthrax vaccines are used in post-exposure setting, then some protection is provided, but they are ineffective compared to antibody therapy
Solution Approach 1:
The patent applies preliminary action by administering pre-formed anti-anthrax antibodies immediately upon exposure, bypassing the time required for vaccine-induced immune response development. This immediate preliminary protection ensures 100% efficacy, resolving the contradiction between protective effect and time delay inherent in vaccine-based approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies provide prophylactic and therapeutic protection by neutralizing anthrax toxins, enhancing survival rates when administered after exposure, and their bioavailability is comparable to intravenous administration, demonstrating effective treatment even when antibiotics alone are insufficient.
Implementation Method 1
an isolated antibody or fragment thereof binds to Bacillus anthracis protective antigen (PA) with high affinity
Implementation Method 2
a composition comprising an antibody which neutralizes B. anthracis toxin
Data Source
AI summary
The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.